Press release
Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NASDAQ: TEM) over potential Wrongdoing
An investigation on behalf of current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares.
Investors who are current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: TEM stocks follows a lawsuit filed against Tempus AI, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: TEM stocks, concerns whether certain Tempus AI, Inc. officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2024 and May 27, 2025, Tempus AI, Inc. branded itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements, that the Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding, that Tempus AI, Inc. often reported on its relationship with long-term customer AstraZeneca as an example, that importantly between August 6, 2024 and May 27, 2025, Tempus AI, Inc. announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI, that the Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market, that Tempus AI, Inc. additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired between August 6, 2024 and May 27, 2025, and that Tempus AI, Inc. claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.
Those who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NASDAQ: TEM) over potential Wrongdoing here
News-ID: 4168937 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of UWM Holdings Corporati …
An investor, who purchased shares of UWM Holdings Corporation (NYSE: UWMC), filed a lawsuit over alleged violations of Federal Securities Laws by UWM Holdings Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of UWM Holdings Corporation (NYSE: UWMC) have certain options and for certain investors are short and strict deadlines running. Deadline: October 13, 2026. NYSE: UWMC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ …
An investigation was announced for current long-term investors in shares of GRAIL, Inc. (NASDAQ: GRAL) concerning potential breaches of fiduciary duties by certain directors of GRAIL, Inc.
Investors who are current long term investors in GRAIL, Inc. (NASDAQ: GRAL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: GRAL…
Lawsuit ALERT: Investors who lost money with shares of Aardvark Therapeutics, In …
An investor, who purchased shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD), filed a lawsuit over alleged violations of Federal Securities Laws by Aardvark Therapeutics, Inc. in connection with certain allegedly false and misleading statements made in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or Aardvark securities between February 13, 2025 and May 14, 2026.
Investors who purchased shares of…
NYSE: RBLX Investigation ALERT: Investors who hold Roblox Corporation (NYSE: RBL …
An investigation was announced for current long-term investors in shares of Roblox Corporation (NYSE: RBLX) concerning potential breaches of fiduciary duties by certain directors of Roblox Corporation.
Investors who are current long term investors in Roblox Corporation (NYSE: RBLX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: RBLX…
More Releases for Tempus
Cancer Informatics Market Set to Booming Growth 2026-2033 | Siemens Healthineers …
The latest study, titled Cancer Informatics Market 2026, published by Coherent Market Insights, delivers high-impact insights into both regional and global markets projected to grow from 2026 to 2033. This comprehensive research provides a detailed evaluation of evolving market dynamics, value chain analysis, key investment pockets, competitive landscape, regional performance, and major market segments. It also offers a thorough assessment of growth drivers, restraints, and emerging opportunities. Designed for business…
AI in Clinical Trials Market: Regaining Its Glory | IBM Watson, Tempus, Oracle
AI in clinical trials refers to the application of artificial intelligence technologies to enhance the efficiency and effectiveness of clinical research processes. This includes utilizing machine learning algorithms for data analysis, patient recruitment, and monitoring outcomes, ultimately aiming to speed up drug development and improve patient outcomes. The integration of AI in clinical trials is transforming the landscape of medical research, enabling more precise and personalized approaches to treatment while…
Genomics In Cancer Care Market is Booming Worldwide |Invitae,Helix, Tempus
HTF MI just released the Global Genomics In Cancer Care Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major Manufacturers are covered: Foundation Medicine (United States), Guardant…
Predictive Disease Analytics Market Is Booming So Rapidly | Tempus, Verily, Pala …
The Global Predictive Disease Analytics Market Size is estimated at $3.5 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 21.4% to reach $20 Billion by 2034.
The latest study released on the Global Predictive Disease Analytics Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Predictive Disease Analytics market study covers significant research data and proofs to be a handy…
AI in Medical Diagnostics Market Is Booming So Rapidly | Aidoc, Tempus, Lunit
USD Analytics recently introduced Global AI in Medical Diagnostics Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, GE Healthcare, Siemens Healthineers, Zebra…
AI in Oncology Market SWOT Analysis by Leading Expert: Tempus, Oncora, PerkinElm …
USD Analytics recently introduced Global AI in Oncology Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, Tempus, GE Healthcare, Siemens Healthineers, Varian…
